Asthma Clinical Research Network

CLINICAL ADVERSE EVENTS

Subject ID: _			 _	
Subject Initials:	<u> </u>			
Visit Number:	0	1		
Visit 1 Date:	month	_ /	 /	

Enter this form when the subject's last visit is completed.

(Clinic Coordinator completed)

If the subject experienced any clinical adverse events (including intercurrent events), complete this log. If no clinical adverse events occurred throughout the entire study, check none, and sign and date this page.

Signature:
Date:

DECODIDEION		2. DATE STARTED (Top Line)	4.	5. DURATION	6. TYPE	7. SEVERITY	8. SERIOUS	9. LIKELIHOOD OF RELATIONSHIP TO TEST DRUG	10. CHANGE IN STUDY MEDICATIONS	11. OUTCOME (Skip if #4 is checked.)	12. TREATMENT REQUIRED
DESCRIPTION OF ADVERSE EVENT		3. DATE STOPPED (Bottom Line)	ONGOING at final visit	Complete ONLY if duration is less than 24	TTENT	TE		- NONE - UNLIKELY (REMOTE) - POSSIBLE - PROBABLE - HIGHLY PROBABLE	1 - DISCONTINUED 2 - REDUCED 3 - INTERRUPTED, BUT RESUMED AT CURRENT DOSE 4 - UNCHANGED 5 - INCREASED	COMPLETELY RECOVERED RECOVERED, BUT WITH LASTING EFFECTS - DEATH	1 - NONE ** 2 - MEDICATION * 3 - HOSPITALIZATION 4
Even.	1.		GOING 8	hours.	I - INTERMITTENT 2 - CONTINUOUS	1 - MILD 2 - MODERATE 3 - SEVERE	1- YES 0 - NO	1 - NONE 2 - UNLIKELY (REMOTE) 3 - POSSIBLE 4 - PROBABLE 5 - HIGHLY PRO	- DISCONTINU - REDUCED - INTERRUPTE BUT RESUMF AT CURREN - UNCHANGEI	1 - COMPLETELY RECOVERED 2 - RECOVERED, BUT WITH LASTING EFFE 3 - DEATH	NONE MEDICAT HOSPITAI OTHER
	ICD9 CODE	MONTH / DAY / YEAR	NO	HOUR(S)	1 - 2 -	1 - 2 - 3 -	1-,	1 - 2 - 3 - 4 - 5 - 5 -	1- 3- 4- 5-	1-2-3-	1 - 2 - 4 - 4 -
1.	CAE_01	CAE_02		CAE_05	CAE_06	CAE_07	CAE_08	CAE_09	CAE_10	CAE_11	CAE_12
EVENT		CAE_03 C	AE_04								
2.		//	□₁								
		//									
3.		//	□₁								
		//	_'								
4.		//	□₁								
	'	//									
5.		//	□₁								
		//									

^{*} Please complete a Serious Adverse Event Reporting Form (SERIOUS). 01/13/97 version 3.2

** Please complete the appropriate Concomitant Medications Log (CMED).

AECLIN

Asthma Clinical Research Network

AIRWATCH™ QUALITY CONTROL

Subject ID:	
Subject Initials:	
Visit Number:	
Current Date://	/vear

Interviewer ID: _

NIH/NHLBI

	(Tecl	hnician completed)				
AIR_01	1.	Serial Number of AirWa	atch™ being tested			
AIR_02	2.	Serial Number of mouth	npiece being tested			
AIR_03	3.	Test date			llaay	l year
AIR_04	4.	Is this a new AirWatch ^T	[™] device being tested	d?	□ ₁ Yes □	\mathbf{Q}_0 No
AIR_04a		If YES , indicate reason		\square_2 " \square_3 "		Gode and the state of the state
					Clinic Use Only	,
			AirWatch™	Jones FVC	Relative Bias	Rank
			(L/Min)	(L/Min)	(AirWatch™ - Jones FVC) * 100 % Jones FVC	smallest to largest
	5.	Trial 1	AIR_05a	AIR_05b	%	
	6.	Trial 2	AIR_06a	AIR_06b	%	_
	7.	Trial 3	AIR_07a	AIR_07b	%	
	8.	Trial 4	AIR_08a	AIR_08b	%	
	9.	Trial 5	AIR_09a	AIR_09b	%	
	Clini	c Use Only				
	Medi	ian Relative Bias	%	Inter-	quartile Range%	
	The I	Median Relative Bias is	the third largest valu	ue of the 5 mea	asures of relative bias.	
	The I	Inter-quartile Range is a	determined by subtra	acting the relati	ve bias of rank 2 from the relative bia	s of rank 4.
	Whe i -15%	n a subject receives a new and +15%, AND the inter-	v AirWatch™ or mout quartile range must be	t hpiece for the t less than 10%.	first time, the median relative bias must	be between
	relati origin inter-	ve bias when the AirWatch [¬] nal inter-quartile range (the	[™] or mouthpiece was fi inter-quartile range wh nce for (i) must be betw	irst dispensed) fi en the AirWatch	btract the original median relative bias (t from the current median relative bias, and ™ or mouthpiece was first dispensed) fro 5% and the difference for (ii) must be less	d (ii) subtract the om the current
AIR_10	10.	Did the AirWatch™ pas	s?		□ ₁ Yes □	1 ₀ No
AID 44	11.	If NO , is this the third m		h this Δir\Match	'	1 ₀ No
AIR_11	11.	If NO, issue a new.	mouthpiece and com	nplete another i	AirWatch™ Quality Control form. Complete another AirWatch™ Quality	



BIOLOGICAL QUALITY CONTROL

Subject ID:	
Subject Initials:	
Visit Number: <u>0</u> <u>1</u>	
Current Date:///	

Interviewer ID: ______

NIH/NHLBI

(Technician completed)

BIO_01	1.	Serial Number of AirV	/atch™ being tested	
BIO_02	2.	Serial Number of mou	thpiece being tested	
BIO_03	3. 4.	Spirometer (L/Min) AirWatch™ (L/Min)	Clinic Use Only	Highest Value
	Bio	logical Relative Bias		
	(Air	Watch™ – Spirometer) Spirometer * 1	00%%	
	The	Biological Relative Bi	as must be between –25% and 25%.	
BIO_05	5.		he Biological Quality Control testing? • continue with Visit 1. Do not complete the rest of this	\square_1 Yes \square_0 No
		If NO, please The subject sho	check the AirWatch™, reinstruct the subject, and retes. uld perform 3 additional AirWatch™ blows which shou the highest spirometry value recorded above (in	
BIO_06	6.	AirWatch™ (L/Min)	Clinic Use Only	Highest Value —————
	Bio	ological Relative Bias	(AirWatch™ – Spirometer) Spirometer * 100% %	
BIO_07	7.	Did the subject pass t	he Biological Quality Control testing?	\square_1 Yes \square_0 No
			of the subject could improve with additional instruction another BIOQC form. Subjects must pass BIOQC beform.	
			not pass BIOQC at this visit, please complete the udy Participation form (TERM).	



CONCOMITANT MEDICATIONS for ASTHMA-RELATED DRUGS

Subject ID:
Subject Initials:
Visit Number: <u>0</u> <u>1</u>
Visit 1 Date:///
month day year

(Clinic Coordinator completed)

At Visit 1: Please list all concomitant medications the subject is taking that are asthma related in the table below. Indicate the name of the medication, dose, units, frequency, route, and start date. Refer to the Concomitant Medications list (MED) for the codes.

Subsequent visits: Please update the table below at each visit. Indicate any new asthma related medications started and any medications that were stopped since the last visit. If the subject is still taking the medication at the end of the study, please check the "ongoing" box. Check the "None" box if the subject has not taken any asthma related concomitant medications during the entire study.

 \square_0 None

CODE	NAME OF MEDICATION	DOSE	UNITS	FREQUENCY	ROUTE	START DATE (MM/DD/YY)	STOP DATE (MM/DD/YY)	ONGOING AT END OF STUDY
CMED_01	1. CMEDNO	CMED_02		CMED_04		CMED_06	CMED_07	CMED_08
	2.	(CMED_03	C	CMED_05]//	//	
	3.					//	/	
	4.					//	//	
	5.					/	/	
	6.					//	/	
	7.					//	//	
	8.					/	/	
	9.					//	//	
	10.					//	/	
	11.					//	/	\Box_1
	12.					//	/	
	13.					//	/	
	14.					/	/	\Box_1
	15.					//	/	

Asthma Clinical Research Network

RUN-IN DIARY CARD

Initials: Date:

Subject ID: 3
Subject Initials:
Return Visit Number:
Return Visit Date:///

DIARY

Please use black ink to complete.

To the subject: If your peak flow is below liters/minute, use your Ventolin®(RESCUE) inhaler as instructed in the handout "If Your Asthma Gets Worse." Contact study personnel if your peak flow does not increase to this value after one hour of Rescue use. If you have used your Ventolin®(RESCUE) inhaler more than puffs/24 hours for the past 48 hours, contact study personnel.								
Day 1: Day 2: Day 3: Day 4: Day 5: Day 6: Day 7: _								Day 7:
	d n Da te	month day	month day	month day	/ month day	/ month day	/ month day	/ month day
			MORNING	G EVALUATIO	N			
	er of times that you woke up due to asthma	DRY_01						
2. Time o	f AM Peak Flow	DRY_02	:	::	:	:	::	:
3. AM Per first thing	ak Flow (liters/min)** recorded in the morning	DRY_03 DRY	_03R					
Ventolin [®]	umber of <u>puffs</u> of (RESCUE) during the night ecord preventive puffs.)	DRY_04						
	5. Shortness of Breath	DRY_05						
Symptoms ⁺⁺ during the night.	6. Chest Tightness	DRY_06						
pton y the	7. Wheezing	DRY_07						
Sym	8. Cough	DRY_08						
	9. Phlegm/Mucus	DRY_09						
			NIGHT-TIN	IE EVALUATIO	ON			
10. Time	of PM Peak Flow	DRY_10	:	::	:	:	:	:
	eak Flow (liters/min)** at bedtime	RY_11 DRY_	11R					
Ventolin [®]	number of <u>puffs</u> of (RESCUE) since you woke ecord preventive puffs.)	DRY_12						
	13. Shortness of Breath	DRY_13						
ptoms ⁺⁺ you woke.	14. Chest Tightness	DRY_14						
nptoms ⁺⁺ you woke	15. Wheezing	DRY_15						
Symp Since)	16. Cough	DRY_16						
<i>O</i> 5	17. Phlegm/Mucus	DRY_17						
			SCHEDULE	D MEDICATIO	ONS			
18. Total since you	number of Azmacort [®] <u>puffs</u> ı woke	DRY_18						
Circle any Ve	d the best of three attempts. the value if you have taken entolin [®] (RESCUE) inhaler ation in the last two hours.	0 = Absent 1 = Mild	Symptom was s	minimally troublesoufficiently troubles		vith normal daily a	rith normal daily a	ctivity or sleep.



ELECTROCARDIOGRAM REPORT

Subject ID:	=
Subject Initials:	
Visit Number:	
Visit Date:////	
month day	year
Interviewer ID:	

(Clinic Coordinator completed)

ECG_01	1.	Ventricular heart rate	beats/min
	2.	Cardiac cycle measurements	
ECG_02A		2a. P - R Interval	seconds
ECG_02B		2b. QRS Duration	seconds
ECG_02C		2c. Q - T Interval	seconds
ECG_03	3.	(If Visit 1, do not complete Question # 3.) Have there been any clinically important changes from Visit 1?	\square_1 Yes \square_0 No
		→ If YES, please complete the Clinical Adverse Event form (AECLIN).	

Asthma Clinical Research Network

ELIGIBILITY CHECKLIST 1

Subject ID: 3 _______

Subject Initials: _______

Visit Number: 0 1 _____/

Visit Date: _____/ ____/ ____/

month day year

Interviewer ID: _

(Subject Interview completed)

E1_01	1.	Did the subject sign the Informed Consent form?	\square_1 Yes	O No	
E1_01A		If YES , record the date the form was signed.	month day		_
E1_02	2.	Are you between the ages of 12 and 65 years inclusive?	□ ₁ Yes	O No	
E1_03	3.	Do you plan to move more than 75 miles away from this clinic in the next year?	1 Yes	□ ₀ No	
E1_04	4.	Have you used any smokeless tobacco products (chew, snuff) in the past year?	1 Yes	□ ₀ No	
E1_05	5.	Have you smoked cigarettes, a pipe, cigars, or any other substance in the past year?	1 Yes	□ ₀ No	
E1_06	6.	Do you have a smoking history greater than 10 pack-years?	1 Yes	\square_{0} No	
E1_06A		Record history in pack-years. (Enter '00' if none)			
E1_07	7.	Have you had a respiratory tract infection in the past 6 weeks?	1 Yes	\square_0 No	
E1_08	8.	Have you experienced a significant asthma attack in the past 6 weeks?	1 Yes	□ ₀ No	
E1_09	9.	Have you experienced a life-threatening asthma attack requiring treatment with intubation and mechanical ventilation in the past 10 years?	1 Yes	□ ₀ No	
E1_10	10.	Are you potentially able to bear children?	\square_1 Yes	\square_{0} No	☐ ₉ N/A
E1_10A		If YES, are you using a birth control method indicated on this reference card? (Show subject the Birth Control Methods reference card.) → Please complete the appropriate Concomitant Medications form if needed.	☐ ₁ Yes	■ ₀ No	
	Initials: Date:				
E1_11	11.	Is the subject eligible? If any of the shaded boxes are filled in, the subject is NOT eligible. If YES, please continue with Visit 1. If NO, please complete the Termination of Study Participation for	☐ ₁ Yes	O No	

Asthma Clinical Research Network

ELIGIBILITY CHECKLIST 2

(Clinic Coordinator completed)

	•	,			
E2_01	1.	Does the subject have current evidence of any of the conditions listed on the Medical Conditions reference card (EXCLMED)? If YES , describe	1 Yes	□ ₀ No	
E2_02	2.	Has the subject taken any medications listed on the Exclusionary Drugs reference card (EXCLDRUG) within the specified time periods? If <i>YES</i> , describe	■ ₁ Yes	□ ₀ No	
E2_03	3.	Is the subject currently taking prescription or over-the-counter medication(s) other than those listed on the Allowed Medications reference card (MEDALLOW)? If YES, describe	■ ₁ Yes	□ ₀ No	
E2_04	4.	Is the subject currently receiving hyposensitization therapy other than an established maintenance regimen?	1 Yes	\square_0 No	
E2_05	5.	Is the subject currently using intranasal steroids, or does the subject anticipate using intranasal steroids during their participation in the study?	☐ ₁ Yes	□ ₀ No	
E2_05A		If YES, please choose one of the following:			
		The subject agrees to stop use of all intranasal steroids for the	e duration of the	e studv.	
		The subject agrees to adhere to a course of beclomethasone dose not to exceed 100 μg in each nostril BID throughout the → Please complete the appropriate Concomitant N	dipropionate at duration of the	a study.	
		The subject does not agree to adhere to the criteria regarding as outlined in the Manual of Operations.	intranasal stero	oid use	
E2_06	6.	Does the subject have an abnormal screening electrocardiogram [ischemic heart disease or arrhythmia; not excluded for occasional (≤ 3/min) atrial or ventricular premature contractions, or clinically insignificant sinus bradycardia]?	■ ₁ Yes	□ ₀ No	
E2_07	7.	Does the subject have a positive pregnancy test?	1 Yes	\square_0 No	☐ ₉ N/A
	Initials: Date:				
E2_08	8.	Is the subject eligible? If any of the shaded boxes are filled in, the subject is NOT eligible. If YES, please continue with Visit 1. If NO, please complete the Termination of Study Participation form (☐ ₁ Yes	□ ₀ No	

Asthma Clinical Research Network NIH/NHLBI

ELIGIBILITY CHECKLIST 3

Subject ID: 3 Subject Initials: ______ Visit Number: <u>0</u> <u>1</u> Visit Date: _____/ ____/ ___day Interviewer ID: __

(Clinic Coordinator completed)

1.	Is the subject able to use a metered dose inhaler properly?	☐ ₁ Yes	O No
2.	Did the subject pass Biological Quality Control (BIOQC) testing at this visit?	☐ ₁ Yes	O No
3.	Is the subject eligible? If either of the shaded boxes is filled in, the subject is NOT eligible. If YES, please continue with this form. If NO, please complete the Termination of Study Participation form (TER	1 Yes	■ ₀ No
4.	Is the subject currently taking inhaled corticosteroids? → If NO, complete Section 1. → If YES, complete Section 2 on the next page.	☐ ₁ Yes	□ ₀ No
Sec			
	ction 1 - Complete for subjects <u>not</u> currently taking inhaled co	rticosteroid	S
5.	Particular 1 - Complete for subjects <u>not</u> currently taking inhaled compose the subject have a prebronchodilator $FEV_1 \le 80\%$ of predicted?	rticosteroid	S No
	3.	 Did the subject pass Biological Quality Control (BIOQC) testing at this visit? Is the subject eligible? If either of the shaded boxes is filled in, the subject is NOT eligible. If YES, please continue with this form. If NO, please complete the Termination of Study Participation form (TEF) Is the subject currently taking inhaled corticosteroids? If NO, complete Section 1. 	 Did the subject pass Biological Quality Control (BIOQC) testing at this visit? □₁ Yes Is the subject eligible? If either of the shaded boxes is filled in, the subject is NOT eligible. If YES, please continue with this form. If NO, please complete the Termination of Study Participation form (TERM). Is the subject currently taking inhaled corticosteroids? □₁ Yes If NO, complete Section 1.

ELIGIBILITY CHECKLIST 3

Section 2 - Complete for subjects <u>currently</u> taking inhaled corticosteroids

E3_08	8.	Does the subject have a prebronchodilator $FEV_1 \ge 40\%$ of predicted? \rightarrow If NO, go to Question #10.	☐ ₁ Yes	o No
E3_09	9.	Does the subject have a prebronchodilator FEV ₁ > 80% of predicted?	\square_1 Yes	□ ₀ No
E3_09A		If YES , does the subject have source documentation of PC_{20} for methacholine \leq 8 mg/ml (ACRN spirometry system and methodology only) in the past 6 months?	☐ ₁ Yes	o No
		(Note: If the subject's PC_{20} for methacholine challenge at this visit \leq 8 mg/ml, this question should be marked 'Yes.')		
E3_09B		If NO , does the subject have source documentation of \geq 12% increase in FEV ₁ in response to aerosolized albuterol (any spirometry system) or of PC ₂₀ for methacholine \leq 8 mg/ml (ACRN spirometry system and methodology only) in the past 6 months?	☐ ₁ Yes	O No
		(Note: If the subject's PC_{20} for methacholine challenge at this visit \leq 8 mg/ml, this question should be marked 'Yes.')		
E3_10	10.	Is the subject eligible? If any of the shaded boxes in Section 2 are filled in, the subject is NOT eligible.	□ ₁ Yes	O No
		 If YES, please continue with Visit 1. If NO, please complete the Termination of Study Participation form (TEI 	RM).	

Asthma Clinical Research Network

ELIGIBILITY CHECKLIST 4

Subject ID: 3 _______Subject Initials: ______

Visit Number: 0 4

Interviewer ID: ______

(Clinic Coordinator completed)

E4_01	1.	Is the subject's pre-bronchodilator ${\sf FEV_1}$ obtained during Visit 4 spirometry less than 55% of predicted?	1 Yes	□ ₀ No
E4_02	2.	Has the subject experienced a significant asthma exacerbation as defined in the Manual of Operations since the first study visit?	■ ₁ Yes	□ ₀ No
E4_03	3.	Has the subject used the Azmacort [®] inhaler less than twice a day on more than 12 days during the run-in period?	1 Yes	□ ₀ No
E4_04	4.	On average during the run-in period, has the subject recorded peak flow measurements and symptoms on the symptom diary card fewer than 5 days per week?	■ ₁ Yes	□ ₀ No
E4_05	5.	Has the subject used the "as-needed" β -agonist an average of \geq 16 puffs per 24 hours during the last week of the run-in period (week 6)?	□ ₁ Yes	□ ₀ No
E4_06	6.	Is there any new information that makes the subject ineligible according to the eligibility criteria? If <i>YES</i> , describe	■ ₁ Yes	□ ₀ No
E4_07	7.	Does the subject wish to withdraw consent from the study?	■ ₁ Yes	□ ₀ No
E4_08	8.	Is there any other reason for which this subject should not be included in the study? If <i>YES</i> , describe	■ ₁ Yes	□ ₀ No
E4_09	9.	Is the subject eligible? If any of the shaded boxes are filled in, the subject is NOT eligible.	□ ₁ Yes	□ ₀ No
		If YES, please continue with the randomization process (<i>next page</i>). If NO, please complete the Termination of Study Participation form (T	ERM).	

ELIGIBILITY CHECKLIST 4

Subject ID: <u>3</u>______

ELIG4

Visit Number: 0 4

10.	Is the subject's pre-bronchodilator FEV ₁ obtained during Visit 4 spirometry greater than 80% of predicted?	☐ ₁ Yes	□ ₀ No
	If NO, skip to Question #12. The subject should be assigned to the s If YES, run the PEF calculator.	SLIC study.	
11.	Is the subject's average PEF variability ≤ 20% during the last	\square_1 Yes	\square_{0} No

	If the subject is eligible to participate in SOCS or SLIC, run the randomization program. If an electronic connection is impossible, call the DCC at (717) 531 - 4262, 8:00 AM - 5:00 PM E.S.T. During the hours 5:00 PM - 9:00 PM E.S.T. call the beeper number and leave a phone number at which you can be contacted.							
E4_12	12. In which study is the subject participating?	\square_1 SOCS \square_2 SLIC						
	Clinic Use Only (SOCS only) Information needed for subject randomization: Age: Sex: Race: PC ₂₀ at visit 4:							
E4_13	13. Study drug packet number.							



SPUTUM FLUID PHASE MEASUREMENTS

Subject ID:	-
Subject Initials:	
Visit Number:	
Visit Date://	
month day	year
Technician ID:	

(Technician completed)

				Non-detectable limit	Quantity not sufficient to dilute
1.	ECP	ECP	mcg/L	ECP_NON	SUFF 🗀
2.	Tryptase	TRYPTASE	mcg/L	TRY_NON _ TRY_	SUFF 🔲

Asthma Clinical Research Network

LABORATORY TESTS

Subject ID:
Subject Initials:
Visit Number:
Visit Date:///
month day year Interviewer ID:

(Clinic Coordinator completed)

	URI	INE TEST RE Run-in: Visit 1 a SOCS: Visit 10 a SLIC: Visit 11	and Visit 4		
LAB_01	1.	Pregnancy test	results	D ₁ Positi	
	Initials: Date:			\square_2 Negar \square_9 N/A	tive
	→ /		- t results are positive, subject must be terminated ERM form and follow study termination procedure		cipation.
		OOD TEST RI ctrolyte Analysi Run-in: Visit 1 SOCS: Visit 10 SLIC: Visit 11			
LAB_02	2.	Potassium			mmol/L
LAB_03	3.	Sodium			mmol/L
LAB_04	4.	Chloride			mmol/L
LAB_05	5.	Carbon Dioxide	·		mmol/L



LONG PHYSICAL EXAM

(Clinic Coordinator completed)

VITAL SIGNS

The subject should sit quietly for five minutes before blood pressure measurements are recorded and maintain this position while all vital signs are taken.

LX_01A LX_01B	1.	Resting blood pressure	systo	 olic	/ diastolic	_ mm Hg
LX_02	2.	Pulse			beats/min	
LX_03	3.	Respiration		_ breat	hs/min	
LX_04	4.	Body Temperature			° F	
LX_05	PULN 5.	MONARY AUSCULTATION Indicate condition of subject. (<i>Check one box only</i>) If applicable, describe sounds:	\square_2	Whee	neezing ze on inspiratior Ititious sounds o ing	
	PHYS	SICAL EXAMINATION				
LX_06	6.	Does the subject have evidence of oral candidiasis?	\Box_1	Yes	\square_0 No	
		If YES, please complete the Clinical Adverse Events form (AECLIN).				

LONG PHYSICAL EXAM

		nse indicate current physical fir BNORMAL, please describe con		hecking the a	appropriate b	oxes below, an	nd	
			Not Done	Normal	Abnormal			
LX_07 LX_08 LX_09 LX_10 LX_11 LX_12 LX_13 LX_14 LX_15 LX_16	7. 8. 9. 10. 11. 12. 13. 14. 15.	Hair and Skin Lymph nodes Eyes (excluding corrective lenses) Ears, Nose, and Throat Respiratory (excluding asthma) Cardiovascular Gastrointestinal Musculoskeletal Neurological Mental Status	$ \begin{array}{c} \square_2 \\ \square_2 \\ \square_2 \end{array} $ $ \begin{array}{c} \square_2 \\ \square_2 \\ \square_2 \end{array} $ $ \begin{array}{c} \square_2 \\ \square_2 \end{array} $ $ \begin{array}{c} \square_2 \\ \square_2 \end{array} $					
LX_17	T	Other	OT complet perienced a st clinic visit Clinical Adv Events wa	e Question # ny new ? erse Events a	form (AECLIN ratory	□ ₁ Yes	□ ₀ No	
		test, report any adverse result Events form (AELAB).	its on a Lab	oratory Adv	erse			



Subject ID: 3
Subject Initials:
Visit Number: 0 1
Visit Date:///
month day year Interviewer ID:

(Subject Interview completed)

IX_01	1.	What is your date of birth?	1
	1.	what is your date or birtin:	month day year
X_02	2.	What is your ethnic background?	 □₁ American Indian or Alaskan Native □₂ Asian or Pacific Islander □₃ Black, not of Hispanic Origin □₄ White, not of Hispanic Origin □₅ Hispanic □₀₀ Other
1X_03	3.	What is your sex?	$egin{array}{cccccccccccccccccccccccccccccccccccc$
	AST	THMA HISTORY	
HX_04	4.	Approximately how old were you when your asthma first	
		appeared? (Check one box only)	\square_1 less than 10 years old \square_2 10-19 years old \square_3 20-29 years old \square_4 30-39 years old \square_5 40-49 years old \square_6 50 years or more \square_8 unknown

MHX_05	5.	How	many years have you had asthma? (Check one box only)		less than 1 - 4 years 1 - 4 years	ırs	
MHX_06	6.	In wh	at season is your asthma the worst? (Check one box only)		\mathbf{Q}_1 Winter \mathbf{Q}_2 Spring \mathbf{Q}_3 Summer \mathbf{Q}_4 Fall \mathbf{Q}_5 Same all \mathbf{Q}_5	year	
	7.	In the	last 12 months, how many: (Enter '00' if none)				
MHX_07A		7a.	Asthma episodes have you had that required emergency care or an unscheduled office visit?	_			
MHX_07B		7b.	Hospitalizations have you had due to asthma?	_			
MHX_07C		7c.	Courses of oral corticosteroid therapy for asthma (such as prednisone or Medrol) have you taken?	_			
MHX_08	8.		you missed any days of work or school due to asthma last 12 months?		1 Yes □	□ ₀ No □	₉ N/A
MHX_08A		If YE S	S , record your best estimate of the number of days missed.	_			
	9.	physi	any of your immediate blood relatives been told by a cian that they have asthma? (Check the 'N/A' box if the ct does not have siblings or children.)				
MHX_09A		9a.	Mother	\square_1 Yes	\square_0 No	☐ ₈ Don't Know	
MHX_09B		9b.	Father	□ ₁ Yes	\square_0 No	□ ₈ Don't Know	
MHX_09C		9c.	Brothers or Sisters	□ ₁ Yes	\square_0 No	□ ₈ Don't Know	□ ₉ N/A
MHX_09D		9d.	Child(ren)	□ ₁ Yes	\square_0 No	Don't Know	□ ₉ N/A

PRIOR ASTHMA TREATMENT

Next, I will read a list of asthma medications. Indicate if you have used the medication. If you have, please indicate to the best of your knowledge, the date last taken.

If Yes, indicate date medication was last taken month / day / year

MHX_10 MHX_10X	10.	Short acting Inhaled Beta-Agonists (MDI) (Bronkaid Mist, Duo-Medihaler, Medihaler-Epi, Primatene Mist and others)	□ ₁ Yes □ ₀ No	□ ₈ Unknown//
MHX_11 MHX_11X	11.	Intermediate acting Inhaled Beta-Agonists (MDI) (Alupent, Brethaire, Brethine, Bronkometer, Maxair, Metaprel, Proventil, Tornalate, Ventolin and others)	\square_1 Yes \square_0 No	□ ₈ Unknown/
MHX_12 MHX_12X	12.	Long acting Inhaled Beta-Agonists (MDI) (Serevent)	□ ₁ Yes □ ₀ No	□ ₈ Unknown//
MHX_13	13.	Asthma medication via a Nebulizer Machine	\square_1 Yes \square_0 No	□ ₈ Unknown
MHX_13X MHX_14 MHX_14X	14.	Intermediate acting Oral Beta-Agonists (Alupent, Brethine, Bricanyl, Metaprel, Proventil, Ventolin and others)	□ ₁ Yes □ ₀ No	□ ₈ Unknown/
MHX_15 MHX_15X	15.	Long acting Oral Beta-Agonists (Repetabs, Volmax)	\square_1 Yes \square_0 No	□ ₈ Unknown/
MHX_16	16.	Short acting Oral Theophylline (Aminophylline and others)	\square_1 Yes \square_0 No	□ ₈ Unknown//
MHX_17 MHX_17X	17.	Sustained release Oral Theophylline (Slo-bid, Theo-Dur, Uniphyl and others)	\square_1 Yes \square_0 No	□ ₈ Unknown/
MHX_18 MHX_18X	18.	Inhaled Anticholinergic (Atrovent)	\square_1 Yes \square_0 No	□ ₈ Unknown//
MHX_19 MHX_19X	19.	Anti-allergic Medications (Intal, Nasalcrom, Tilade and others)	\square_1 Yes \square_0 No	□ ₈ Unknown/
MHX_20	20.	Oral Steroids (Prednisone, Medrol and others)	\square_1 Yes \square_0 No	□ ₈ Unknown//

 Subject ID:
 3

 Visit Number:
 0
 1

			If Yes, indicate date medication was last taken month / day / year
MHX_21	21.	Inhaled Steroids (Azmacort, Beclovent, Vanceril, AeroBid, Flovent and others)	□ ₁ Yes □ ₀ No □ ₈ Unknown <u> </u>
MHX_21A		If YES , 21a. Indicate most recent type.	 beclomethasone diproprionate (1 puff = 42μg) (e.g., Beclovent, Vanceril) triamcinolone acetonide (1 puff = 100μg) (e.g., Azmacort) flunisolide (1 puff = 250μg) (e.g., AeroBid) fluticasone (1 puff = 44, 110, or 220μg) (e.g., Flovent)
MHX_21B		21b. Indicate most recent daily puffs.	puffs
MHX_21C		21c. Indicate most recent daily use.	μg
MHX_21D		21d. Indicate most recent duration.	\square_1 less than 1 month \square_2 1 - 6 months \square_3 greater than 6 months
MHX_22 MHX_22X	22.	Leukotriene Antagonist / 5L0 Inhibitors (Zafirlukast (Accolate), Zileuton)	\square_1 Yes \square_0 No \square_8 Unknown $______$

Have you had any	diseases,	illnesses,	or surgeries	related t	to the	following	areas?
, , , , , , , , , , , , , , , , , , ,	,,						

					If Yes, Comment
MHX_23	23.	Skin	\square_1 Yes	\square_0 No	
MHX_24	24.	Blood, Lymph, or Immune Systems	□ ₁ Yes	\square_0 No	
MHX_25	25.	Eyes	\square_1 Yes	\square_0 No	
MHX_26	26.	Ears, Nose, or Throat	□ ₁ Yes	\square_0 No	
MHX_27	27.	Breasts	\square_1 Yes	\square_0 No	
MHX_28	28.	Endocrine	□ ₁ Yes	\square_0 No	
MHX_29	29.	Lung	□ ₁ Yes	\square_0 No	
MHX_30	30.	Heart and Blood Vessels	\square_1 Yes	\square_0 No	
MHX_31	31.	Liver or Pancreas	\square_1 Yes	\square_0 No	
MHX_32	32.	Kidneys or Urinary Tract System	\square_1 Yes	\square_0 No	
MHX_33	33.	Reproductive System	\square_1 Yes	\square_0 No	
MHX_34	34.	Stomach or Intestines	□ ₁ Yes	\square_0 No	
MHX_35	35.	Muscles or Bones	□ ₁ Yes	\square_0 No	
MHX_36	36.	Nervous System	□ ₁ Yes	\square_0 No	
MHX_37	37.	Psychiatric	□ ₁ Yes	\square_0 No	
MHX_38	38.	Other	\square_1 Yes	\square_0 No	



METHACHOLINE CHALLENGE TESTING

Subject ID:
Subject Initials:
Visit Number:
Visit Date://
month day year Interviewer ID:

(Clinic Coordinator completed)

Complete this form only if the subject has successfully completed the Spirometry Testing form (SPIRO).

METH_01	1.	Has the subject had an acute asthma attack requiring oral steroids (prednisone or a similar drug) in the past 4 weeks?	■ ₁ Yes	□ ₀ No
METH_02	2.	Has the subject had any other severe acute illness in the past 4 weeks? If <i>Yes</i> , has the subject received permission from the supervising physician to proceed with the methacholine challenge testing? Name of physician:	☐ ₁ Yes	□ ₀ No □ ₀ No
METH_03	3.	Does the subject have a baseline (pre-diluent) FEV_1 less than 55% of predicted FEV_1 ? At visit 1 use the prebronchodilator FEV_1 value from the SPIRO form as the For visit 4 through final visit: For SLIC, use the 1 hour post-salmeterol FEV_1 from the SPIRO form For SOCS, use the prebronchodilator FEV_1 value from the SPIRO form	as the baseline	reference.
METH_04	4.	Is there any other reason the subject should not proceed with the methacholine challenge testing? If <i>Yes</i> , explain	■ ₁ Yes	□ ₀ No
METH_05	5.	Is the subject eligible to proceed with the diluent (solution #0) pulmonary function testing for the methacholine challenge? If any of the shaded boxes are filled in, the subject is NOT eligible for the methacholine challenge. If NO, do NOT complete the rest of this form. If possible, the baseline pulmonary function testing and the methacholine rescheduled within the visit window.	1 Yes line challenge	No No should

METHACHOLINE CHALLENGE

Subject ID: _	
Visit Number:	

METHACHOLINE CHALLENGE TEST (Technician completed)

			, ,					
	Clini	c Use O	Only					
	At visit 1 use the prebronchodilator FEV ₁ value from the SPIRO form as the baseline reference.							
	For v	For	prough final visit: In SLIC, use the 1 hour post-salmeterol FEV ₁ from the SPIRO form as the baseline reference. In SOCS, use the prebronchodilator FEV ₁ value from the SPIRO form as the baseline reference.					
		Baseli	line FEV ₁ prior to methacholine challenge					
		A.	FEV ₁ L					
		В.	FEV ₁ (% predicted)					
	Meth	acholin	ne Reversal Reference Value					
METH_06	6.	PC ₂₀	Time methacholine challenge was completed. (based on 24-hour clock)	Ü				
	7.	lf subj	ect's FEV ₁ after standard reversal from methacholine challenge eject is continuing with sputum induction, standard reversal = 4 puffs albuterol. eject is not continuing with sputum induction, standard reversal = 2 puffs albuterol.					
METH_07a		7a.	FEV ₁	. L				
METH_07b		7b.	FEV ₁ (% predicted)	% predicted				
METH_07c		7c.	Time of FEV ₁ in Question #7a (based on 24-hour clock)	-				
METH_07d		7d.	Was the FEV ₁ from Question #7a \geq the methacholine reversal reference value in the gray box above?	0 No				

→ If YES, stop form and continue with remaining visit procedures.

Subject ID: _ METHACHOLINE CHALLENGE Visit Number: ☐₁ Yes **L**o No METH_08 8. Was additional treatment used in the first hour? → If NO, skip to Question #10. → If YES, please complete the appropriate Concomitant Medications form, if needed. \square_1 Yes \square_0 No 8a. Additional albuterol by MDI METH_08a → If NO, skip to Question #8b. \square_1 two \square_2 four \square_3 > four Number of additional puffs of albuterol administered METH08a1 8ai. $\bigsqcup_{1 \text{ Yes}} \bigsqcup_{0 \text{ No}}$ 8b. Nebulized Beta-agonist METH 08b \square_1 Yes \square_0 No 8c. Subcutaneous epinephrine METH_08c ☐₁ Yes METH_08d 8d. Implementation of clinic emergency protocol or algorithm \square_1 Yes METH_08e 8e. Other 9. Subject's FEV₁ after additional treatment within first hour. METH 09a 9a. FEV₁ ____ L METH 09b 9b. FEV₁ (% predicted) Time of FEV₁ in Question #9a (based on 24-hour clock) 9c. METH 09c □₁ Yes □₀ No METH_09d 9d. Was the FEV₁ from Question #9a \geq the methacholine reversal reference value in the gray box on page 2 of this form? → If YES, stop form and continue with remaining visit procedures. \square_1 Yes \square_0 No METH_10 10. Was additional treatment used after one hour? → If NO, skip to Question #11. → If YES, please complete the appropriate Concomitant Medications form, if needed. ☐₁ Yes **U**₀ No METH_10a 10a. Additional albuterol by MDI → If NO, skip to Question #10b. \square_1 two \square_2 four \square_3 > four METH10a1 Number of additional puffs of albuterol administered **□**₁ Yes METH 10b 10b. **Nebulized Beta-agonist J**₁ Yes METH_10c 10c. Subcutaneous epinephrine

01/13/97 version 3.2

10d.

10e.

10f.

10q.

METH_10d

METH_10e

METH_10f

METH_10g

Form Page 3 of 4

→ If YES, please complete the Serious Adverse Event form (SERIOUS).

Implementation of clinic emergency protocol or algorithm

Treatment in the emergency room

Overnight hospitalization

Other __

METHA

 \bigcup_{0} No

☐₁ Yes

 \square_1 Yes

☐₁ Yes

☐₁ Yes

METHACHOLINE CHALLENGE

Subject ID:
Visit Number:

	11.	Subject's f	inal FEV ₁ after methacholine challenge.		
METH_11a		11a.	FEV ₁	·	L
METH_11b		11b.	FEV ₁ (% predicted)		% predicted
METH_11c		11c.	Time of FEV ₁ from Question #11a (based on 24-hour clock)		
METH_11d		11d.	Was the FEV ₁ from Question #11a ≥ the methacholine reversal reference value in the gray box on page 2 of this form? → If NO, complete the source documentation box below.	☐ ₁ Yes	□ ₀ No
			Physician signature: Date:// Time:::		



ANORA number: _____

(Collector completed)

NO_ANORA

NITRIC OXIDE MEASUREMENTS

Subject ID:
Subject Initials:
Visit Number:
Visit Date://
month day year Collector ID:

Nitric Oxide measurements should be taken after completing the spirometry checklist and prior to performing baseline spirometry.

(Reader completed)

	Balloon Id	Time Collected (based on 24-hour clock)	Time Read (based on 24-hour clock)	Measurement (ppb)
	NO_BAL1a	NO_BAL1b	NO_BAL1c	NO_BAL1d
	NO_BAL2a	NO_BAL2b	NO_BAL2c	NO_BAL2d
	NO_BAL3a	NO_BAL3b	NO_BAL3c	NO_BAL3d
NO_DATE	Date balloons were	e read:///	<u> </u>	
NO_READ	Reader ID:			
	Comments:			



Subject ID:
Subject Initials:
Visit Number:
Visit Date:///
month day year
Interviewer ID:

(Subject completed)

Please tell us how much you have been limited <u>by your asthma during the last 2 weeks</u> in each of your 5 most important activities. Refer to the Quality of Life Activities form (QOLACT) for your list of activities. If you have not done the activity in the last 2 weeks, leave the question blank.

HOW <u>LIMITED</u> HAVE YOU BEEN DURING THE LAST 2 WEEKS IN THESE ACTIVITIES?

		Not at all Limited	A Little Limitation	Some Limitation	Moderate Limitation	Very Limited	Extremely Limited	Totally Limited
QOL_01	1. Activity 1			□ ₃	☐ ₄			
QOL_02	2. Activity 2							
QOL_03	3. Activity 3			\square_3				
QOL_04	4. Activity 4			\square_3				 7
QOL_05	5. Activity 5			\square_3				 7
QOL_06	How much discomfort or distress have	None	Very Little	Some	Moderate Amount	A Good Deal		A Very Great Deal
	you felt over the last 2 weeks as a result of CHEST TIGHTNESS?			\square_3	\square_4			\square_7

Initials: Date:

Subject ID: _	
Visit Number:	

IN GENERAL, <u>HOW MUCH OF THE TIME</u> DURING THE LAST 2 WEEKS DID YOU:

			None of the Time	Hardly Any of the Time	A Little of the Time	Some of the Time	A Good Bit of the Time	Most of the Time	All of the Time
QOL_07	7.	Feel CONCERNED ABOUT HAVING ASTHMA?			\square_3				
QOL_08	8.	Feel SHORT OF BREATH as a result of your asthma?			\square_3				
QOL_09	9.	Experience asthma symptoms as a RESULT OF BEING EXPOSED TO CIGARETTE SMOKE?			\square_3				
QOL_10	10.	Experience a WHEEZE in your chest?			\square_3				 7
QOL_11	11.	Feel you had to AVOID A SITUATION OR ENVIRONMENT BECAUSE OF CIGARETTE SMOKE?					□ ₅	□ ₆	
001.10	4.5		None	Very Little	Some	Moderate Amount	A Good Deal		A Very Treat Deal
QOL_12	12.	How much discomfort or distress have you felt over the last 2 weeks as a result of COUGHING?			\square_3				

Subject ID: _	
Visit Number:	

IN GENERAL, <u>HOW MUCH OF THE TIME</u> DURING THE LAST 2 WEEKS DID YOU:

			None of the Time	Hardly Any of the Time	A Little of the Time	Some of the Time	A Good Bit of the Time	Most of the Time	All of the Time
QOL_13	13.	Feel FRUSTRATED as a result of your asthma?			\square_3				
QOL_14	14.	Experience a feeling of CHEST HEAVINESS?			\square_3				
QOL_15	15.	Feel CONCERNED ABOUT THE NEED TO USE MEDICATION for your asthma?			\square_3				
QOL_16	16.	Feel the need to CLEAR YOUR THROAT?			\square_3				
Q0L_17	17.	Experience asthma symptoms as a RESULT OF BEING EXPOSED TO DUST?			\square_3				
QOL_18	18.	Experience DIFFICULTY BREATHING OUT as a result of your asthma?			\square_3	 4			
QOL_19	19.	Feel you had to AVOID A SITUATION OR ENVIRONMENT BECAUSE OF DUST?			\square_3				
QOL_20	20.	WAKE UP IN THE MORNING WITH ASTHMA SYMPTOMS?			\square_3				
Q0L_21	21.	Feel AFRAID OF NOT HAVING YOUR ASTHMA MEDICATION AVAILABLE?			\square_3				
QOL_22	22.	Feel bothered by HEAVY BREATHING?			\square_3				
QOL_23	23.	Experience asthma symptoms as a RESULT OF THE WEATHER OR AIR POLLUTION?					 5		
QOL_24	24.	Were you WOKEN AT NIGHT by your asthma?			\square_3				
QOL_25	25.	AVOID OR LIMIT GOING OUTSIDE BECAUSE OF THE WEATHER OR							

Subject ID: _	
Visit Number:	

IN GENERAL, <u>HOW MUCH OF THE TIME</u> DURING THE LAST 2 WEEKS DID YOU:

			None of the Time	Hardly Any of the Time	A Little of the Time	Some of the Time	A Good Bit of the Time	Most of the Time	All of the Time
QOL_26	26.	Experience asthma symptoms as a RESULT OF BEING EXPOSED TO STRONG SMELLS OR PERFUME?				 4			
QOL_27	27.	Feel AFRAID OF GETTING OUT OF BREATH?			\square_3				
QOL_28	28.	Feel you had to AVOID A SITUATION OR ENVIRONMENT BECAUSE OF STRONG SMELLS OR PERFUME?				 4			
QOL_29	29.	Has your asthma INTERFERED WITH GETTING A GOOD NIGHT'S SLEEP?			\square_3	 4			
QOL_30	30.	Have a feeling of FIGHTING FOR AIR?			\square_3				
QOL_31	31.	Think of the OVERALL RANGE OF ACTIVITIES that you would have liked to have done during the last 2 weeks. How much has your range of activities been limited by your asthma?	No Limitation		Very Few Not Done	\square_4	Several Not Done	$\square_{_6}$	Most Not Done
QOL_32	32.	Overall, among ALL THE ACTIVITIES that you have done during the last 2 weeks, how limited have you been by your asthma?	Not at all Limited	A Little Limitation	Some Limitation	Moderate Limitation	Very Limited	Extremely Limited	Totally Limited



SERIOUS ADVERSE EVENT REPORTING FORM

Subject ID: _	
Subject Initials:	
Visit Number:	
Current Date:	
Interviewer ID:	month day year

NIH/NHLBI

(Clinic Coordinator completed)

This form must be faxed to the DCC at (717) 531-4359 within 72 hours of notification of a serious event. Also fax the Clinical Adverse Events Log (AECLIN), the Concomitant Medications Log (CMED_AS), and any relevant source documents.

SER_01	1.	Desci	ription of Adverse Event (ICD9 Code)		
		Desci	ribe:		
SER_02	2.		interval between taking the study drug (last dose before toms) and subsequent onset of symptoms?	<u>—</u> —	
SER_03	3.	Unit o	of time for above interval	$ \square_1 \text{ second(s)} $ $ \square_2 \text{ minute(s)} $ $ \square_3 \text{ hour(s)} $ $ \square_4 \text{ day(s)} $	
	4.	Why	was the event serious?		
SER_04a		4a.	Fatal Event?	☐ ₁ Yes	\square_{0} No
SER_04b		4b.	Life-threatening event?	☐ ₁ Yes	\square_{0} No
SER_04c		4c.	Inpatient hospitalization required?	☐ ₁ Yes	\square_{0} No
SER_04d		4d.	Hospitalization prolonged?	☐ ₁ Yes	\square_{0} No
SER_04e		4e.	Disabling or incapacitating?	☐ ₁ Yes	\square_{0} No
SER_04f		4f.	Overdose?	☐ ₁ Yes	\square_{0} No
SER_04g		4g.	Cancer?	☐ ₁ Yes	\square_{0} No
SER_04h		4h.	Congenital anomaly?	☐ ₁ Yes	\square_{0} No
SER_04i		4i.	Serious laboratory abnormality with clinical symptoms?	\square_1 Yes	\square_{0} No
SER_04j		4j.	Other	☐ ₁ Yes	\square_{0} No
	5.	What	, in your opinion, caused the event?		
SER_05a		5a.	Toxicity of study drug?	\square_1 Yes	O No
SER_05b		5b.	Withdrawal of study drugs?	☐ ₁ Yes	O ₀ No

SERIOUS ADVERSE EVENT Visit Number: ____ \square_{0} No \square_1 Yes SER_05c 5c. Concurrent medication? If YES, describe _____ SER_05d 5d. Concurrent disorder? If **YES**, describe _____ SER_05e Other event? 5e. If **YES**, describe _____ DO NOT ENTER QUESTIONS # 6 - 7: FOR REPORTING PURPOSES ONLY. If subject died, cause of death: 6. ☐₁ Yes **J**₀ No 7. Was an autopsy performed? If YES, attach report or send as soon as possible. Reporting Investigator: Name: Address: Signature: _____ ____/___/____/____ Date:

Comments (discuss any relevant laboratory data or other assessments which help explain the event):



SHORT PHYSICAL EXAM

	(Clir	nic Coordinator completed)		
	VITA	AL SIGNS		
	mea	subject should sit quietly for five minutes before blood pressure surements are recorded and maintain this position while all vital as are taken.		
SX_01a	1.	Resting blood pressure	systolic	/mm Hg
SX_02	2.	Pulse		beats/min
	PUL	MONARY AUSCULTATION		
SX_03	3.	Indicate condition of subject. (<i>Check one box only</i>) If applicable, describe sounds:	Whe	wheezing eze on inspiration or expiration entitious sounds other than zing
SX_04	4.	Does the subject have evidence of oral candidiasis? If YES, please complete the Clinical Adverse Events form (AECLIN).	☐ ₁ Yes	□ ₀ No
	[Physician/Nurse signature: Date:// ime:::		
	ADV	ERSE EVENTS		
SX_05	5.	Ask the subject: Have you experienced any new medical conditions since the last clinic visit?	☐ ₁ Yes	O No
		If YES, please complete the Clinical Adverse Events form (AECLIN).		
		If any of the Clinical Adverse Events warrants a laboratory test, report any adverse results of such tests on a Laboratory Adverents form (AELAB)	se	

01/13/97 version 3.2

Form Page 1 of 1

SEXAM



HEALTH STATUS QUESTIONNAIRE SF-36

Subject ID:	
Subject Initials:	
Visit Number:	
Visit Date:////	ear
Interviewer ID:	_

(Subject completed)

Below are questions about your health in general and questions about your health as it relates specifically to asthma. Please read and answer the questions carefully. If you are not sure about how to answer a question, please give the best answer you can.

SF36_01	1.	In general, would you say your health is:	\square_1 Excellent \square_2 Very Good \square_3 Good \square_4 Fair \square_5 Poor
SF36_02	2.	Compared to ONE YEAR AGO, how would you rate your health in general NOW?	\square_1 Much better now than one year ago \square_2 Somewhat better now than one year ago \square_3 About the same \square_4 Somewhat worse now than one year ago \square_5 Much worse now than one year ago

Initials: Date:

HEALTH STATUS QUESTIONNAIRE

Subject ID: _	
Visit Number:	

The following questions are about activities you might do during a typical day. Does YOUR HEALTH now limit you in these activities? If so, how much?

			Yes, Limited a Lot	Yes, Limited a Little	No, Not Limited at All
SF36_03a	3a.	VIGOROUS ACTIVITIES, such as running, lifting heavy objects, participating in strenuous sports		\square_2	\square_3
SF36_03b	3b.	MODERATE ACTIVITIES, such as moving a table, pushing a vacuum cleaner, bowling, or playing golf	\square_1	\square_2	\square_3
SF36_03c	3c.	Lifting or carrying groceries	\square_1		\square_3
SF36_03d	3d.	Climbing SEVERAL flights of stairs	\square_1		\square_3
SF36_03e	3e.	Climbing ONE flight of stairs			\square_3
SF36_03f	3f.	Bending, kneeling, or stooping	\square_1	\square_2	\square_3
SF36_03g	3g.	Walking MORE THAN A MILE	\square_1		\square_3
SF36_03h	3h.	Walking SEVERAL BLOCKS			\square_3
SF36_03i	3i.	Walking ONE BLOCK	\square_1		
SF36_03j	3j.	Bathing or dressing yourself	\square_1		\square_3
		RING THE PAST 4 WEEKS, have you had any of the following probactivities AS A RESULT OF YOUR PHYSICAL HEALTH?	lems with your	work or other re	egular
SF36_04a	4a.	Cut down on the AMOUNT OF TIME you spent on work or other	activities	□ ₁ Yes □	O No
SF36_04b	4b.	ACCOMPLISHED LESS than you would like		□ ₁ Yes □	O No
SF36_04c	4c.	Were limited in the KIND of work or other activities		□ ₁ Yes □	\mathbf{D}_{0} No
SF36_04d	4d.	Had DIFFICULTY performing the work or other activities (for example, it took extra effort)		□ ₁ Yes □	O No

HEALTH STATUS QUESTIONNAIRE

Subject ID:	
Visit Number:	

DURING THE PAST 4 WEEKS, have you had any of the following problems with your work or other regular daily activities AS A RESULT OF ANY EMOTIONAL PROBLEMS (such as feeling depressed or anxious)?

SF36_05a	5a.	Cut down on the AMOUNT OF TIME you spent on work or other activities	\square_{1} Yes \square_{0} No
SF36_05b	5b.	ACCOMPLISHED LESS than you would like	\square_{1} Yes \square_{0} No
SF36_05c	5c.	Didn't do work or other activities as CAREFULLY as usual	\square_1 Yes \square_0 No
SF36_06	6.	DURING THE PAST 4 WEEKS, to what extent has your physical health or emotional problems interfered with your normal social activities with family, friends, neighbors, or groups?	\square_1 Not at all \square_2 Slightly \square_3 Moderately \square_4 Quite a bit
SF36_07	7.	How much shortness of breath have you had during the PAST 4 WEEKS?	\square_{4} Cutte a bit \square_{5} Extremely \square_{1} None \square_{2} Very mild \square_{3} Mild \square_{4} Moderate \square_{5} Severe
SF36_08	8.	DURING THE PAST 4 WEEKS, how much did pain interfere with your normal work (including both work outside the home and housework)?	Solution of the second of the

HEALTH STATUS QUESTIONNAIRE

Subject ID: _	
Visit Number:	

These questions are about how you feel and how things have been with you during the PAST 4 WEEKS. For each question, please give the one answer that comes closest to the way you have been feeling.

How much of the time during the PAST 4 WEEKS...

			All of the Time	Most of the Time	A Good Bit of the Time	Some of the Time	A Little of the Time	None of the Time
SF36_09a	9a.	Did you feel full of pep?	\square_1	\square_2	\square_3	\square_4	\square_5	\square_6
SF36_09b	9b.	Have you been a very nervous person?	\square_1	\square_2	\square_3	\square_4	\square_5	\square_6
SF36_09c	9c.	Have you felt so down in the dumps that nothing could cheer you up?		\square_2	\square_3	\square_4	\square_5	\square_6
SF36_09d	9d.	Have you felt calm and peaceful?	\square_1	\square_2	\square_3	\square_4	\square_5	\square_6
SF36_09e	9 e.	Did you have a lot of energy?	\square_1	\square_2	\square_3	\square_4	\square_5	\square_6
SF36_09f	9f.	Have you felt downhearted and blue?	\square_1	\square_2	\square_3	\square_4	\square_5	\square_6
SF36_09g	9g.	Did you feel worn out?	\square_1	\square_2	\square_3	\square_4	\square_5	\square_6
SF36_09h	9h.	Have you been a happy person?	\square_1	\square_2	\square_3	\square_4	\square_5	\square_6
SF36_09i	9i.	Did you feel tired?	\square_1	\square_2	\square_3	\square_4	\square_5	\square_6

HEALTH STATUS QUESTIONNAIRE

Subject ID: _	
Visit Number:	

SF36_10	10.	DURING THE PAST 4 WEEKS, how much of the time physical health or emotional problems interfered with activities (like visiting with friends, relatives, etc.)?		[\square_1 All of the \square_2 Most of \square_3 Some of \square_4 A little of	the time the time the time	
	How	TRUE or FALSE is each of the following statemen	Definitely	Mostly	Don't	Mostly	Definitely
SF36_11a	11a.	I seem to get sick a little easier than other people.	True	True	Know	False	False
SF36_11b	11b.	I am as healthy as anybody I know.	\square_1	\square_2	\square_3	\square_4	\square_5
SF36_11c	11c.	I expect my health to get worse.	\square_1	\square_2	\square_3	\square_4	\square_5
SF36_11d	11d.	My health is excellent.	\square_1	\square_2	\square_3	$\square_{_4}$	\square_5



Subject ID:	
Subject Initials:	
Visit Number:	
Current Date://	
Interviewer ID:	/ear

(Clinic Coordinator completed)

This form must be completed each time a subject experiences an asthma exacerbation according to the definition below.

	1.		zing, or shortness of breath along with any of the following conditions?	iess,	
SAE_01a		1a.	An increase in rescue inhaler use of \geq 8 puffs per 24 hours over baseline rescue inhaler use for a period of 48 hours?	1 Yes	□ ₀ No
SAE_01b		1b.	Use of rescue inhaler \geq 16 total puffs per 24 hours for a period of 48 hours?	1 Yes	□ ₀ No
SAE_01c		1c.	PEF which did not increase to 65% of reference levels after 60 minutes of rescue beta agonist use?	1 Yes	□ ₀ No
SAE_01d		1d.	Symptoms which persisted after 60 minutes of rescue beta-agonist use?	Yes	□ ₀ No
SAE_02	2.	asthm	oral or parenteral corticosteroids given to the subject for his/her na exacerbation as a result of rescue intervention or by the on of the treating physician?	■ ₁ Yes	□ ₀ No
	If SL	LIC subje OCS sub	shaded boxes are filled in, the subject experienced a significant asthma ect → Please complete this form and continue with the treatment failure ject and the shaded box in Question #2 is checked → Please complete the failure packet.	packet.	ontinue with the
	If th	e subjec	et does not meet the above criteria as defined in the Manual of Operations	s,DO NOT COMI	PLETE THIS FORM.
	If the subject has experienced a significant asthma exacerbation but has not yet completed the RUN-IN period, STOP. The subject is ineligible for the study. → Please complete the Termination of Study Participation form (TERM).				-

SAE_03	3.	Date of significant asthma exacerbation	lll
SAE_04	4.	Did the subject seek care for the asthma exacerbation? → If NO, skip to Question #6.	\square_1 Yes \square_0 No
	5.	What type of care was sought?	
SAE_05a		5a. Study Investigator?	\square_1 Yes \square_0 No
SAE_05a1		If YES, indicate type of contact.	Scheduled clinic visit Unscheduled clinic visit D ₃ Phone contact
SAE_05b		5b. Primary Care or Other Physician? Name of physician:	\square_1 Yes \square_0 No
SAE_05b1		If YES, indicate type of contact.	Scheduled clinic visit Unscheduled clinic visit Phone contact
SAE_05c		5c. Emergency Room visit? Name of hospital:	\square_1 Yes \square_0 No
SAE_06	6.	Was the subject hospitalized? Name of hospital: → If YES, please complete the Serious Adverse Event Reporting Form (SERIOUS).	\square_1 Yes \square_0 No
		If YES,	
SAE_06a		6a. Duration of hospital stay?	days
SAE_06b		6b. Was intubation or ventilation assistance required?	\square_1 Yes \square_0 No
SAE_07	7.	Did the asthma exacerbation require treatment with inhaled, oral, or intravenous glucocorticoids?	\square_1 Yes \square_0 No
		→ If YES, please complete the appropriate Concomitant Medications form, if needed.	

SAE_08	8.	Was the asthma exacerbation treated as outlined in the Manual of Operations? If <i>NO</i> , describe	□ ₁ Yes □ ₀ No
SAE_09	9.	Was the significant asthma exacerbation related to the routine pulmonary function testing? (Check one box only)	Definitely related Probably related Relationship undetermined Probably not related Definitely not related
SAE_10	10.	Was the significant asthma exacerbation related to the Methacholine Challenge testing? (Check one box only)	Definitely related Probably related Relationship undetermined Probably not related Definitely not related
SAE_11	11.	Was the significant asthma exacerbation related to the Sputum Induction? (Check one box only)	Definitely related Probably related Relationship undetermined Probably not related Definitely not related
SAE_12	12.	Was the significant asthma exacerbation related to the Bronchoscopy? (Check one box only)	Definitely related Probably related Relationship undetermined Probably not related Definitely not related

Subject ID:	
Visit Number:	

	(Sub	ject Interview completed)	
SAE_13	13.	Interval of time since last exacerbation	$ \begin{array}{ccc} \square_1 & < 1 \text{ month} \\ \square_2 & 1 - 2 \text{ months} \\ \square_3 & 3 - 6 \text{ months} \\ \square_4 & 7 - 12 \text{ months} \\ \square_5 & > 1 \text{ year} \end{array} $
SAE_14	14.	Over what time period did the subject's asthma symptoms worsen prior to being diagnosed as having a significant asthma exacerbation?	$ \begin{array}{cccc} $
SAE_15	15.	Was the asthma exacerbation resolved solely by increasing PRN use of the rescue inhaler?	\square_1 Yes \square_0 No

Subject ID: _	
Visit Number:	

In the table below, rate each of the following triggering factors with respect to their relationship to the current exacerbation.

- 1 = Definitely related
- 2 = Probably related
- 3 = Relationship undetermined
- 4 = Probably not related
- 5 = Definitely not related

	Triggering factors	Relationship to current asthma exacerbation*
SAE_16	16. Allergen exposure (cat, dog, pollen)	
SAE_17	17. Viral respiratory tract infection (common cold)	
SAE_18	18. Sinus infection	
SAE_19	19. Exercise	
SAE_20	20. Weather conditions	
SAE_21	21. Irritant exposure (smoke, pollution, perfume)	
SAE_22	22. Occupational exposure	
SAE_23	23. Emotional stress	
SAE_24	24. Failure to understand protocol directions	
SAE_25	25. Poor compliance	
SAE_26	26. Health care access problem	
SAE_27	27. Other - Specify:	

^{*} based upon information obtained from the patient and discussed by the clinic coordinator and physician

SAE_28	28.	Did allergen exposure occur?	\square_1 Yes	\square_0 No
		→ If NO, skip to question 29.		
SAE_28a		28a. Based upon the subject's allergy skin test, does the time of year	\square_1 Yes	\square_0 No
		of the current exacerbation correlate with these results in your		

ragweed and fall, mold and summer/fall, etc.)

		28b.	a clinica		gy skin test, did the subjocany of the following wit cerbation?				
SAE_28b1			28bi.	Dog			Ţ	1 Yes	\square_{0} No
SAE_28b2			28bii.	Cat				1 Yes	\square_0 No
SAE_28b3			28biii.	Pollen			Ţ	1 Yes	\square_0 No
SAE_28b4			28biv.	Mold				1 Yes	\square_0 No
SAE_28b5			28bv.	Dust mites				1 Yes	\square_0 No
SAE_29	29.	week	prior to h	experience any allergic is/her exacerbation? to question 30.	c rhinitis symptoms durii	ng the	Ţ	☐ ₁ Yes	□ ₀ No
		29a.	Which o	of the following sympton	ns did the subject exper	ience?			
						Not Present	Mild	Moderat	e Severe
SAE_29a1			29ai.	Watery rhinorrhea		\square_0			\square_3
SAE_29a2			29aii.	Purulent rhinorrhea		\square_0	\square_1	\square_2	\square_3
SAE_29a3			29aiii.	Post nasal drainage		\square_0		\square_2	\square_3
SAE_29a4			29aiv.	Nasal itching		\square_0		\square_2	\square_3
SAE_29a5			29av.	Palatal itching		\square_0			\square_3
SAE_29a6			29avi.	Sneezing		\bigsqcup_0			\square_3
SAE_29a7			29avii.	Cough		\square_0		\bigsqcup_{2}	\square_3
SAE_29a8			29aviii.	Headache		\square_0			\square_3
SAE_29a9			29aix.	Anosmia		\square_0			\square_3
SAE_29a0			29ax.	Malaise		\bigsqcup_0	\square_1	\square_2	\square_3
SAE_30	30.		•	experience any "cold" :	symptoms during the		Ţ	☐ _{1 Yes}	□ ₀ No
				to auestion 31.					

Subject ID:	
Visit Number:	

30a. Which of the following "cold' symptoms did the subject experience?

			Not Present	Mild	Moderate	Severe
SAE_30a1		30ai. Watery rhinorrhea	\square_0	\square_1	\square_2	\square_3
SAE_30a2		30aii. Purulent rhinorrhea	\square_0	\square_1		\square_3
SAE_30a3		30aiii. Post nasal drainage	\square_0	\square_1	\square_2	\square_3
SAE_30a4		30aiv. Headache	\square_0	\square_1	\square_2	\square_3
SAE_30a5		30av. Sore throat	\square_0	\square_1	\square_2	\square_3
SAE_30a6		30avi. Fever	\square_0		\square_2	\square_3
SAE_30a7		30avii. Cough	\square_0		\square_2	\square_3
SAE_30a8		30aviii. Malaise	\square_0			\square_3
SAE_30a9		30aix. Muscle aches	\square_0	\square_1	\square_2	\square_3
SAE_31	31.	Did sinusitis occur within the last week? → If NO, skip to question 32.		[☐ _{1 Yes} [□ ₀ No
		31a. If sinusitis occurred within the last week, how was it	t diagnosed?	Г		_
SAE_31a1		31ai. History and exam		_	1 Yes	O No
SAE_31a2		31aii. Sinus radiographs		Ļ	1 Yes	O No
SAE_31a3		31aiii. CT scan of sinuses		Ţ	\square_{1} Yes	\square_{0} No
SAE_31b		31b. Which statement best describes the subject's clinic experience with sinus disease?	al	[\bigcap_{0} NOT a Acute \bigcap_{2} Subacu	ıte
SAE_32	32.	Did exercise contribute to the current exacerbation? Name of activity:			1 Yes [□ ₀ No
SAE_33	33.	Did weather conditions contribute to the current exacerbati → If NO, skip to question 34.	ion?		1 Yes [O No

Subject ID: _	
Visit Number:	

		33a.	What w	reather conditions were felt to be contributory?		
SAE_33a1			33ai.	Weather too hot?	Language 1 Yes	\square_0 No
SAE_33a2			33aii.	Weather too cold?	\square_1 Yes	\square_0 No
SAE_33a3			33aiii.	Weather too dry?	\square_1 Yes	\square_0 No
SAE_33a4			33aiv.	Weather too humid?	\square_1 Yes	\square_{0} No
SAE_33a5			33av.	Change in weather? Describe change:	☐ ₁ Yes	□ ₀ No
SAE_34	34.		-	osure contribute to the current exacerbation? to question 35.	☐ ₁ Yes	□ ₀ No
		34a.	Did the	subject have relevant exposure to the following irritants?		
SAE_34a1			34ai.	Cigarette smoke	\square_1 Yes	\square_0 No
SAE_34a2			34aii.	Indoor air pollution Please specify type of indoor air pollution:	☐ ₁ Yes	□ ₀ No
SAE_34a3			34aiii.	Outdoor air pollution Please specify type of outdoor air pollution:	☐ ₁ Yes	□ ₀ No
SAE_34a4			34aiv.	Perfume/cologne	\square_1 Yes	\square_0 No
SAE_34a5			34av.	Aerosols	\square_1 Yes	\square_0 No
SAE_34a6			34avi.	Other Please specify other:	\square_1 Yes	\square_0 No
SAE_35	35.		•	nal exposure contribute to the current exacerbation? to question 36.	\square_1 Yes	\square_0 No
		Pleas	e specify	substance involved:		
SAE_35a		35a.	. ,	is the first exposure to the above substance?	\square_1 Yes	\square_{0} No
SAE_35b		35b.	Did mu	Itiple exposures occur to this substance?	\square_1 Yes	\square_0 No
SAE_36	36.	→ If	NO, skip	stress contribute to the current exacerbation? to question 37. be the stressful situation:	☐ ₁ Yes	□ ₀ No
SAE_36a		36a.	Was thi	is the first time the stressful situation occurred?	\square_1 Yes	\square_{0} No
SAE_36b		36b.	Does th	nis stressful situation occur often?	\square_1 Yes	\square_0 No

Subject ID: _	
Visit Number:	

SAE_37	37.	Did failure to understand the protocol directions contribute to the current exacerbation? → If NO, skip to question 38. → If YES, please describe the failure.	☐ ₁ Yes	□ ₀ No
SAE_38	38.	Did poor compliance contribute to the current exacerbation? → If NO, skip to question 39. → If YES, please describe the problem with compliance.	□ ₁ Yes	□ ₀ No
SAE_39	39.	Did a problem with access to health care contribute to the current exacerbation? → If NO, skip to question 40. → If YES, please describe the problem.	□ ₁ Yes	□ ₀ No
SAE_40	40.	Are there any other important factors that contributed to the current exacerbation? → If YES, please describe.	□ ₁ Yes	□ ₀ No



ALLERGY SKIN TEST RESULTS

Subject ID: 3 _______

Subject Initials: _______

Visit Number: 0 1 ______/

Visit Date: ______/ _____/

month day year

Interviewer ID: _______/

(Clinic Coordinator completed)

SKIN_PST	A .	Has the subject had a previous skin test using ACRN procedures?	\square_1 Yes	□ ₀ No		
SKIN_PTD		If <i>YES</i> , date of previous skin test	month day	/		
			n photocopy of the			
If any of the medications listed in the skin test section of the ACRN Manual of Operations were taken within the exclusionary periods, reschedule the skin testing procedure.						
SKIN_TS] B.	Skin test site	\square_1 back \square_2 forea	rm		
SKIN_TT		Time subject skin tested (based on 24-hour clock)		<u> </u>		
SKIN_TE		Time skin tests evaluated (based on 24-hour clock)				

ALLERGY SKIN TEST RESULTS

Subject ID:	3	
Visit Number:	0	<u>1</u>

A reaction is defined as a wheal of at least 3 mm in diameter and an erythema at least 10 mm in diameter. For each allergen, indicate whether there was a reaction. If yes, transfer the tracing of each wheal and record the longest diameter and the diameter at the perpendicular midpoint in mm.

	SKIN_01	Was there a reaction? \square_0 No \square_1 Yes		SKIN_08	Was there a reaction? \square_0 No \square_1 Yes
		Largest Wheal			Largest Wheal
	SKIN_01a	Diameter mm		SKIN_08a	Diameter mm
		Perpendicular Wheal			Perpendicular Wheal
1. Diluting Fluid	SKIN_01b	Diameter mm	8. Alternaria	SKIN_08b	Diameter mm
	SKIN_02	Was there a reaction? \square_0 No \square_1 Yes		SKIN_09	Was there a reaction? \square_0 No \square_1 Yes
		Largest Wheal			Largest Wheal
	SKIN_02a	Diameter mm		SKIN_09a	Diameter mm
		Perpendicular Wheal			Perpendicular Wheal
2. Tree Fluid	SKIN_02b	Diameter mm	9. Cladosporium	SKIN_09b	Diameter mm
	SKIN_03	Was there a reaction? \square_0 No \square_1 Yes		SKIN_10	Was there a reaction? \square_0 No \square_1 Yes
		Largest Wheal			Largest Wheal
	SKIN_03a	Diameter mm		SKIN_10a	Diameter mm
		Perpendicular Wheal			Perpendicular Wheal
3. Grass Mix	SKIN_03b	Diameter mm	10. Aspergillus	SKIN_10b	Diameter mm
	SKIN_04	Was there a reaction? \square_0 No \square_1 Yes		SKIN_11	Was there a reaction? \square_0 No \square_1 Yes
		Largest Wheal			Largest Wheal
	SKIN_04a	Diameter mm		SKIN_11a	Diameter mm
		Perpendicular Wheal			Perpendicular Wheal
4. Ragweed	SKIN_04b	Diameter mm	11. D. Farinae	SKIN_11b	Diameter mm

ALLERGY SKIN TEST RESULTS

	SKIN_05	Was there a reaction? \square_0 No \square_1 Yes		SKIN_12	Was there a reaction? \square_0 No \square_1 Yes
		Largest Wheal			Largest Wheal
	SKIN_05a	Diameter mm		SKIN_12a	Diameter mm
		Perpendicular Wheal			Perpendicular Wheal
5. Weed Mix	SKIN_05b	Diameter mm	12. D. Pteryn	SKIN_12b	Diameter mm
	SKIN_06	Was there a reaction? \square_0 No \square_1 Yes		SKIN_13	Was there a reaction? \square_0 No \square_1 Yes
		Largest Wheal			Largest Wheal
	SKIN_06a	Diameter mm		SKIN_13a	Diameter mm
		Perpendicular Wheal			Perpendicular Wheal
6. Dogs	SKIN_06b	Diameter mm	13. Cockroach	SKIN_13b	Diameter mm
	SKIN_07	Was there a reaction? □0 No □1 Yes		SKIN_14	Was there a reaction? □0 No □1 Yes
		Largest Wheal			Largest Wheal
	SKIN_07a	Diameter mm		SKIN_14a	Diameter mm
		Perpendicular Wheal			Perpendicular Wheal
7. Cats	SKIN_07b	Diameter mm	14. Histamine	SKIN_14b	Diameter mm

Asthma Clinical Research Network

SPIROMETRY TESTING

_

NIH/NHLBI

(Subject Interview completed)

SPIR_01	1.	(If Visit 1, do not complete Question #1.)		
		Have you used your Ventolin® (RESCUE) inhaler in the past 6 hours?	1 Yes	□ ₀ No
		If the time is less than 6 hours, pulmonary function		
		testing must be rescheduled.		
SPIR_02	2.	(Visit 5 through Last Visit Only)	_	_
		(SOCS subjects) Have you used Inhaler 2 in the past 48 hours?	1 Yes	□ ₀ No
		(SLIC subjects) Have you used Inhaler 2 in the past 12 hours?		
SPIR_03	3.	Have you consumed caffeine in the past 8 hours? Examples: Caffeinated colas (Pepsi, Coke), Coffee,	1 Yes	□ ₀ No
		Mello-Yello, Mountain Dew, Tea		
SPIR_04	4.	Have you used medications with caffeine in the past 8 hours?	Yes	\square_0 No
		Examples: Anacin, Darvon compound, Esgic, Excederin, Fiorinal, Fioricet, No Doz, Norgesic, Vivarin		
ODID OF	_	Llava vas announced any feed containing placked on house	□ vaa	□ Na
SPIR_05	5.	Have you consumed any food containing alcohol or beverages containing alcohol in the past 8 hours?	1 Yes	□ ₀ No
SPIR_06a	6a.	Have you used fexofenadine (e.g. Allegra) or chlorpheniramine	1 Yes	□ ₀ No
31 IK_00a	ua.	(e.g. Chlor-Trimeton) in the past 48 hours?	— 1 les	— 0 NO
SPIR_06b	6b.	Have you used pseudoephedrine (e.g. Sudafed) or oxymetazoline	1 Yes	□ ₀ No
31 IK_00D	OD.	(e.g. Afrin) in the past 48 hours?	103	
SPIR_07	7.	(For Sputum Induction only) Have you used any cough or cold	1 Yes	□ ₀ No
		preparations (e.g. expectorants, decongestants, or antitussives) in the past 48 hours?	—,	
		→ If Yes, reschedule visit within visit window.		
SPIR_08	8.	Have you had a respiratory tract infection or any other pulmonary	\square_1 Yes	□ ₀ No
31 111_00	0.	infection since the last visit?	— 103	
SPIR_09	9.	At this time, is your asthma worse because of recent exposure	\square_1 Yes	\square_0 No
		to triggers (for example: cold air, smoke, allergens, or recent exercise)?		
SPIR_10	10.	Is there any other reason you should not proceed with the	■ _{1 Yes}	□ ₀ No
		pulmonary function testing?	ı	V
		If YES, explain		

SPIROMETRY TESTING

SPIR_11

11. Is the subject eligible to proceed with the pulmonary function testing? *If any of the shaded boxes are filled in, the subject is NOT eligible for testing.*

1Yes ONO

- If YES, please continue.
- If NO, do NOT complete page 2 or 3 unless this is a SOCS or SLIC treatment failure visit.

 If this is a regular protocol visit, the pulmonary function testing should be rescheduled within the visit window.

SPIR_12

12. Height (without shoes)

Height should be measured at every visit if subject is \leq 21 years old and only at Visit 1 if subject is > 21 years old.

BASELINE PULMONARY FUNCTION TESTING (*Technician completed*)

SPIR_13

13. Time spirometry started (based on 24-hour clock)

The best effort reflects the trial where the sum of FEV₁ and FVC are maximized.

SPIR_14a

14. Results of best effort

FVC ____. ___L

SPIR_14b

FEV₁ ____._

FEV₁

SPIR_14c

SPIR_14d

PEFR ____ . ___ L/S

SPIR_14e

FEF₂₅₋₇₅ _____L/S

% predicted

SPIROMETRY TESTING

Visits 5 through 11: Compare the subject's prebronchodilator FEV_1 in Question #14 to the prebronchodilator value obtained at Visit 4 for possible treatment failure status. See SOCS/SLIC Manual of Operations for details.

Subject ID:	
Visit Number:	

THIS PAGE IS FOR SLIC VISITS 4 THROUGH 11 AND SLIC TREATMENT FAILURE VISITS ONLY

SPIR_15a	15. Results of best effort post-salmeterol	FVC	L
SPIR_15b		FEV ₁	L
SPIR_15c		FEV ₁	% predicted
SPIR_15d		PEFR	L/S
SPIR_15e		FEF ₂₅₋₇₅	L/S
	Visits 5 through 11: Compare the subject's post-salmeterol FEV ₁ in Queat Visit 4 for possible treatment failure status. See	stion #15 to the post-salme SOCS/SLIC Manual of Ope	eterol value obtained rations for details.
	If the subject did not complete salmeterol reversibil	ity testing please provide a	n explanation below.



SPUTUM INDUCTION LAB **VALUES**

Subject ID:
Subject Initials:
Visit Number:
Visit Date:///
Interviewer ID

(Technician completed)

	Tot	al and Differential Cell Counts		
SLAB_01	1.	Total Cell Count	·	x 10 ⁵ /m
SLAB_02	2.	Squamous Cells	·	%
		parameters below are calculated following exclusion of amous cells.		
SLAB_03	3.	Total Cell Count	·	x 10 ⁵ /m
SLAB_04	4.	Epithelial Cells	<u> </u>	_ %
SLAB_05	5.	Macrophages	·	_ %
SLAB_06	6.	Neutrophils	·	_ %
SLAB_07	7.	Eosinophils	·	_ %
SLAB_08	8.	Lymphocytes	·	_ %
SLAB_09	9.	Did the subject's sputum sample reveal ≥ 80% squamous cells?	1 Yes	o No

If the shaded box in Question #9 is filled in, the sputum sample should not be sent for overreading.



Subject ID:	_
Subject Initials:	
Visit Number:	
Visit Date://	
month day Interviewer ID:	year

(Technician completed)

SPUT_01	1.	At visi than 4 samp	it 4, was the subject able to continue sputum induction for more 4 minutes and able to produce a satisfactory induced sputum le (≥ 1 ml and < 80% squamous cells)? NO, stop here. DO NOT proceed with sputum induction.	☐ ₁ Yes	□ No
		→ If \	YES, please continue with this form.		
SPUT_02	2.	Did th	ne subject complete the methacholine challenge?	\square_1 Yes	\square_0 No
		→ If I	NO, skip to Question #3.		
SPUT_02a		2a.	Subject's FEV ₁ after all reversal from methacholine challenge	·	L
SPUT_02b		2b.	Subject's FEV_1 (% predicted) after all reversal from methacholine challenge		% predicted
SPUT_02c		2c.	Was the subject's FEV ₁ from Question $\#2a \ge$ the methacholine reversal reference value on page 2 of the METHA form?	☐ ₁ Yes	O No
SPUT_02d		2d.	Is the FEV ₁ from Question #2b \geq 60% predicted?	☐ ₁ Yes	o No
			the shaded boxes is filled in, STOP here. DO NOT proceed with sputu f the shaded boxes is filled in, Skip to Question #6 on the next page.	m induction.	
	(Foi	r subj	ects who did not complete methacholine challenge)		
SPUT_03	3.	Subje	ct's FEV ₁ 15 minutes after 4 puffs of albuterol	·	L
SPUT_04	4.	Subje	ect's FEV ₁ 15 minutes after 4 puffs of albuterol (% predicted)		% predicted
SPUT_05	5.	Is the	subject's post-albuterol $FEV_1 \ge 60\%$ predicted?	1 Yes	o No
	If the	e shade	ed box in Question #5 is filled in, STOP here. DO NOT proceed with s	outum induct	ion.

SPUT_06	6.	(If Visit 1, do not complete Question #6.) What was the duration of sputum induction the first time it exceeded 4 minutes, not including current visit? (Duration of sputum induction at current visit should not exceed this.)	<u> </u>	minutes
	7.	Subject's FEV ₁ immediately after completion of sputum induction		
SPUT_07a		7a. FEV ₁	<u> </u>	L
SPUT_07b		7b. FEV ₁ (% predicted)		% predicted
SPUT_07c		7c. Time of FEV ₁ from Question #7a (based on 24-hour clock)		
SPUT_08	% c	hange in FEV ₁ (Question #2a or 3 - Question #7a) x 100 : % r sputum induction Question #2a or 3		minutes
SPUT_09	9.	Volume of sputum sample at this visit		ml
SPUT_10 SPUT_11	10. 11.	Was the subject's sputum sample volume ≥ 1 ml at this visit? Did the subject tolerate sputum induction for > 4 minutes at this visit?	☐ ₁ Yes	O No
SPUT_12	12.	Is the sample adequate for analysis of squamous cells? If either of the shaded boxes is filled in, the sputum sample should not be sent for analysis of squamous cell counts.	☐ ₁ Yes	O No

Subject ID:	
Visit Number:	

Complete pages 3 and 4 only if the subject has a fall in FEV_1 (from post-albuterol baseline) of > 20% during or immediately after sputum induction.

		JIINIC U	se uniy			
		-	Induction Reference Value (Question #2a or Question #3) x 0.90 =	L		
	13.	Subje	ct's FEV ₁ after initial 2 puffs of albuterol following sputum induction			
SPUT_13a		13a.	FEV ₁		_•	L
SPUT_13b		13b.	FEV ₁ (% predicted)			% predicted
SPUT_13c		13c.	Time of FEV ₁ from Question #13a (based on 24-hour clock)			<u> </u>
SPUT_13d		13d.	Was the FEV ₁ from Question #13a \geq the sputum induction reversal reference value in the gray box above?		₁ Yes	O No
			→ If YES, stop form and continue with remaining visit procedures.			
SPUT_14	14.	Was a	additional treatment used in the first hour?		₁ Yes	O No
			NO, skip to Question #16. YES, please complete the appropriate Concomitant Medications forn if needed.	n,		
SPUT_14a		14a.	Additional albuterol by MDI		1 Yes	O No
			→ If NO, skip to Question #14b.			
SPUT14a1			14ai. Number of additional puffs of albuterol administered	\square_1 two	\square_2 four	\square_3 > four
SPUT_14b		14b.	Nebulized Beta-agonist		1 Yes	O No
SPUT_14c		14c.	Subcutaneous epinephrine		1 Yes	\square_0 No
SPUT_14d		14d.	Implementation of clinic emergency protocol or algorithm		1 Yes	\square_{0} No
SPUT_14e		14e.	Other		1 Yes	O No
	15.	Subie	ct's FEV ₁ after additional treatment within the first hour			
	10.	•	'			
SPUT_15a		15a.	FEV ₁		-·	L
SPUT_15b		15b.	FEV ₁ (% predicted)			% predicted

Subject ID:	
Visit Number:	

SPUT_15c		15c.	Time of FEV ₁ from Question #15a (based on 24-hour clock)		-
SPUT_15d		15d.	Was the FEV ₁ from Question #15a ≥ the sputum induction reversal reference value in the gray box on page 3 of this form? → If YES, stop form and continue with remaining visit procedures.	☐ ₁ Yes	□ ₀ No
SPUT_16	16.	→ If I	additional treatment used after one hour? NO, skip to Question #17. YES, please complete the appropriate Concomitant Medications form, if needed.	□ ₁ Yes	□ ₀ No
SPUT_16a		16a.	Additional albuterol by MDI → If NO, skip to Question #16b.	☐ ₁ Yes	O No
SPUT16a1			•	two \square_2 for	our \square_3 > four
SPUT_16b		16b.	Nebulized Beta-agonist	\square_1 Yes	\square_0 No
SPUT_16c		16c.	Subcutaneous epinephrine	Yes	$\square_0^{}$ No
SPUT_16d		16d.	Implementation of clinic emergency protocol or algorithm	\square_1 Yes	\square_0 No
SPUT_16e		16e.	Treatment in the emergency room	\square_1 Yes	\square_0 No
SPUT_16f		16f.	Overnight hospitalization	\square_1 Yes	\square_0 No
			→ If YES, please complete the Serious Adverse Event form (SERIOUS)		
SPUT_16g		16g.	Other	□ ₁ Yes	□ ₀ No
	17.	Subje	ct's final FEV ₁ after sputum induction		
SPUT_17a		17a.	FEV ₁	·	L
SPUT_17b		17b.	FEV ₁ (% predicted)		% predicted
SPUT_17c		17c.	Time of FEV ₁ from Question #17a (based on 24-hour clock)		
SPUT_17d		17d.	Was the FEV ₁ from Question #17a \geq the sputum induction reversal reference value in the gray box on page 3 of this form?	☐ ₁ Yes	□ ₀ No
			→ If NO, complete the source documentation box below.		
			Physician signature:		



TERMINATION OF STUDY PARTICIPATION

Subject ID:	
Subject Initials:	
Visit Number:	
Current Date:	
	month day year
Interviewer ID:	

	(Clir	nic Coordinator completed)		
	Plea	ase indicate the reason for termination of study participation.		
TERM_01	1.	(SOCS Visit 13 and SLIC Visit 11 Only) Has the subject completed the study? → If YES, skip to the SIGNATURES section on page 2.	☐ ₁ Yes	□ ₀ No
TERM_02	2.	Is the subject withdrawing from the study due to pregnancy?	\square_1 Yes	□ ₀ No
		nitials: Date:		
TERM_03	3.	(Visit 1 through Visit 4 Only) During the run-in period, has the subject experienced a significant asthma exacerbation as defined in the Manual of Operations?	☐ ₁ Yes	□ ₀ No
TERM_04	4.	(Visit 1 through Visit 4 Only) Has the subject been deemed ineligible according to any eligibility criteria other than a significant exacerbation?	☐ ₁ Yes	□ ₀ No
TERM_05	5.	Has the subject withdrawn consent? If <i>YES</i> , indicate the primary reason. 1 no longer interested in participating 2 no longer willing to follow protocol 3 access to clinic is difficult (location, transportation, parking) 4 unable to make visits during clinic hours 5 moving out of the area 4 unable to continue on study due to personal constraints 7 dissatisfied with asthma control 8 unable to continue due to medical condition unrelated to asthma 9 side effects of study medications	□ ₁ Yes	□ ₀ No
		□ ₁₀ treatment failure □ ₁₁ other		

TERMINATION OF STUDY PARTICIPATION

TERM_06	6.	Has the subject been lost to follow-up?	☐ ₁ Yes	\square_0	No
TERM_07	7.	Did a physician initiate subject termination?	☐ ₁ Yes	\square_0	No
TERM_08	8.	 Has the subject experienced a serious adverse event (e.g., hospitalization, death, etc.)? → If YES, complete the Serious Adverse Event Reporting form (SERIOUS). 	☐ ₁ Yes	\square_0	No
TERM_09	9.	(SOCS Visits 10 - 13 Only) Has the subject been assigned drop-out status during the single blind run-out period?	☐ ₁ Yes		No
	SIGNATURES Please complete the following section regardless of the reason for termination of study participation. I verify that all information collected on the ACRN SOCS or SLIC data collection forms for this subject is correct to the best of my knowledge and was collected in accordance with the procedures outlined in the ACRN SOCS or SLIC Protocol and Manual of Operations.				
		TERM_S1 Clinic Coordinator Signature	month	RM_DT1	 year
	_	TERM_S2 Principal Investigator Signature		RM_DT2	year year